DoseLog guides
The GLP-1 guide library.
Deep, plain-language guides on every part of GLP-1 treatment: each medication's side effects, the drugs still in trials, the head-to-head comparisons, and the women's-health questions, all with sources you can check. Not medical advice.
Latest · 54 stories
Every GLP-1 medication compared: the full matrix
Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, side by side: the active drug, form, what each is approved for, typical weight loss, and the landmark trial behind it.
8 min read →
Zepbound vs Mounjaro: the same drug, two labels
Zepbound and Mounjaro are both tirzepatide from Eli Lilly, at the same doses. The difference is what each is approved for and what insurance will cover. Here is how to read it.
7 min read
Retatrutide vs tirzepatide: triple agonist versus the current leader
Retatrutide is an investigational triple agonist with striking phase 2 numbers; tirzepatide (Zepbound, Mounjaro) is the approved dual-agonist leader. What the comparison does and does not tell you.
7 min read
CagriSema vs Zepbound: the amylin combo versus the approved leader
CagriSema is Novo's investigational cagrilintide-plus-semaglutide combination; Zepbound is Lilly's approved tirzepatide. What the trial numbers show, and why availability decides today.
7 min read
Orforglipron vs tirzepatide: the pill versus the injection
Orforglipron is an investigational once-daily GLP-1 pill; tirzepatide (Zepbound, Mounjaro) is the approved injection. What the trade-off between convenience and effect size actually looks like.
7 min read
Zepbound for sleep apnea: what SURMOUNT-OSA actually showed
Zepbound (tirzepatide) is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Here is what the SURMOUNT-OSA trial found, and what it means for CPAP.
7 min read
How to inject a GLP-1: a calm, step-by-step walkthrough
A simple, nerve-settling guide to injecting Mounjaro, Zepbound, Wegovy, Ozempic, or Saxenda: preparing the pen, the injection itself, rotating sites, and disposing safely.
6 min read
Ozempic vs Wegovy: the same drug, two labels, one honest answer
Ozempic and Wegovy are both semaglutide from the same maker. The real difference is what each is approved for, the top dose, and what insurance will cover. Here is how to choose.
7 min read
Pemvidutide: the GLP-1/glucagon agonist aimed at fat and liver
Pemvidutide is an investigational GLP-1/glucagon dual agonist targeting obesity and liver disease, with trials suggesting weight loss that spares more muscle.
7 min read
VK2735: Viking's GLP-1/GIP agonist, in both shot and pill
VK2735 is an investigational GLP-1/GIP dual agonist from Viking Therapeutics, in injectable and oral forms. Early trials reported strong weight loss. What's known.
7 min read
Ecnoglutide: the weekly GLP-1 analog advancing in China
Ecnoglutide is an investigational once-weekly GLP-1 analog from Sciwind, with trials in China reporting solid weight loss and glucose control. What's known.
6 min read
Bimagrumab: the muscle-building drug studied with GLP-1s
Bimagrumab is not a GLP-1: it is an antibody that builds muscle while cutting fat, studied alongside semaglutide to improve the quality of weight loss.
7 min read
Trulicity (dulaglutide) side effects: the weekly diabetes GLP-1
Trulicity is weekly dulaglutide for type 2 diabetes. Nausea led at ~12 to 21% in trials, with a needle-free auto-injector. Side effects, timing, and red flags.
8 min read
Survodutide: the GLP-1/glucagon dual agonist in late trials
Survodutide pairs GLP-1 with glucagon receptor activity, targeting weight and liver disease. Phase 2 reported up to ~19% weight loss. What trials show so far.
7 min read
Mazdutide: the GLP-1/glucagon agonist approved first in China
Mazdutide is a GLP-1/glucagon dual agonist that reached approval in China for weight and diabetes. Trial results, its side-effect profile, and global status.
7 min read
Amycretin: the GLP-1/amylin combo in oral and injectable trials
Amycretin pairs GLP-1 with amylin in one molecule, in both pill and injection forms. Early trials reported striking weight loss. What's known so far.
7 min read
GLP-1 before and after: realistic results, by the numbers
What GLP-1 before-and-after really looks like: average loss by drug and month, why photos mislead, the non-scale wins, and how to document your own honestly.
9 min read
Ozempic face: why it happens, whether it lasts, and how to soften it
Ozempic face is facial fat loss from rapid weight loss, not a drug side effect on skin. Why cheeks hollow, whether it reverses, and what genuinely helps.
8 min read
GLP-1 maintenance dose: how it's set and why it isn't always the max
A maintenance dose is the one you settle on long-term, not automatically the highest. How prescribers choose it, why lower can be right, and when to revisit it.
8 min read
GLP-1 diet plan: how to eat when appetite is small
A GLP-1 diet plan is not a restriction list; it is a structure for a shrinking appetite. Protein-first framework, a sample day, and how to adapt it to any cuisine.
9 min read
GLP-1s and pancreatitis: the warning, the data, the symptoms
Pancreatitis sits on every GLP-1 label, yet pooled trial data shows no significant increase. What the warning means, who should be careful, and the symptoms that matter.
8 min read
Which GLP-1 is right for you? The honest decision guide
Semaglutide, tirzepatide, liraglutide, pills, pens: the real decision runs through access, diabetes status, effect size, and routine fit. The map, in one place.
9 min read
GLP-1s and your heart: what the outcome trials actually proved
SELECT showed semaglutide cut major cardiac events by 20% in people with CVD and overweight. The heart story, from blood pressure to the heart-rate footnote.
8 min read
GLP-1s in perimenopause: the messy-middle years, handled honestly
Perimenopause scrambles weight, cycles, and sleep while fertility quietly persists. What GLP-1s fix, what they can't, and the contraception rule everyone forgets.
8 min read
GLP-1 side effects: the complete plain-language overview
Nearly all common GLP-1 side effects trace to one mechanism: a slowed gut. What is common, what is rare, when each shows up, and the red flags that need a doctor.
10 min read
Wegovy side effects: what the 2.4 mg dose really brings
Wegovy is semaglutide at its highest approved dose, so GI side effects run higher than Ozempic's: nausea ~44% in trials. Timelines, management, and red flags.
9 min read
Zepbound side effects: what to expect on weekly tirzepatide
Zepbound (tirzepatide) reported nausea in roughly a quarter of trial users, scaling with dose. What is common, when it shows up, and the red flags that need a doctor.
9 min read
Mounjaro side effects: the practical guide for weekly tirzepatide
Mounjaro (tirzepatide for type 2 diabetes) reported nausea in roughly 12 to 18% of trial users. What is common, the hypoglycemia caveat, and the red flags.
9 min read
Semaglutide side effects: one molecule, three products, one pattern
Ozempic, Wegovy, and Rybelsus are all semaglutide, and their side effects differ mainly by dose and route. The unified picture, timelines, and red flags.
9 min read
Tirzepatide side effects: the dual-agonist picture, plainly
Tirzepatide (Mounjaro, Zepbound) pairs GLP-1 with GIP. Its side effects are the familiar GI list, scaling with dose. Rates, timelines, and the red flags.
9 min read
Oral semaglutide (Rybelsus) side effects: the daily-tablet picture
The semaglutide tablet shares the injectable's side-effect list at a daily rhythm: nausea around 11 to 20% in trials, plus the empty-stomach ritual. The full picture.
8 min read
Saxenda (liraglutide) side effects: the daily-injection original
Saxenda is daily liraglutide, the class's older workhorse: nausea ~39% in trials, gentler averages, generics arriving. What to expect and when it still makes sense.
8 min read
Wegovy vs Zepbound: the head-to-head, honestly read
In the only head-to-head trial, Zepbound averaged ~20% weight loss to Wegovy's ~14%. What that gap means, where it doesn't apply, and how to actually choose.
8 min read
Ozempic vs Mounjaro: the diabetes head-to-head, honestly read
SURPASS-2 ran tirzepatide against semaglutide 1 mg in type 2 diabetes: Mounjaro won on A1c and weight, with a caveat in the comparison dose. The full picture.
8 min read
Retatrutide: what trials report so far on the triple agonist
Retatrutide is an investigational triple agonist (GLP-1, GIP, glucagon) with phase 2 weight loss up to ~24%. What the trials report on side effects, plainly.
8 min read
Orforglipron: the once-daily GLP-1 pill, and what trials report
Orforglipron is a small-molecule GLP-1 pill with no food or water restrictions. Phase 3 reported ~12% average weight loss; GI effects led the side-effect list.
8 min read
CagriSema: semaglutide plus amylin, and what trials report
CagriSema pairs semaglutide with cagrilintide, an amylin analog. Phase 3 reported ~23% average weight loss. What it is, what trials show, and when it could arrive.
8 min read
GLP-1s and your gallbladder: the risk, explained without panic
GLP-1 users see more gallstone problems, mostly because rapid weight loss itself raises the risk. How big it really is, the symptoms that matter, and prevention.
8 min read
GLP-1s and thyroid cancer risk: what the boxed warning actually says
The thyroid warning on every GLP-1 label comes from rat studies; human data hasn't confirmed the risk. Who truly can't take these drugs, and what symptoms matter.
8 min read
GLP-1s for PCOS: what's known, what's off-label, what to watch
PCOS and GLP-1s intersect at insulin resistance. What the evidence shows on weight, cycles, and fertility, the contraception caveat, and what to track.
9 min read
GLP-1s and menopause weight gain: what actually helps
Menopause reshapes weight: slower metabolism, more visceral fat, less muscle. What GLP-1s can and can't fix, the muscle and bone caveats, and what to track.
9 min read
GLP-1s after pregnancy: timing, breastfeeding, and the honest answers
GLP-1s are not recommended while breastfeeding, and the postpartum year has its own rules. When starting makes sense, what the labels say, and what to do meanwhile.
8 min read
Your first month on a GLP-1: what to track from day one
The first month on a GLP-1 sets your baseline. Six things worth tracking from day one: dose, side effects, protein, water, weight trend, and how you feel.
8 min read
Where to inject a GLP-1: sites, rotation, and why it matters
GLP-1 injections go subcutaneously in the abdomen, thigh, or upper arm, and absorption is equivalent across all three. Why rotation matters and how to stay comfortable.
7 min read
How much protein do you need on a GLP-1?
Most people on a GLP-1 do well aiming for 1.2 to 1.6 g of protein per kg of goal body weight. Why the target rises during weight loss, and how to hit it when appetite is small.
8 min read
How much water should you drink on a GLP-1?
A practical hydration target for GLP-1 users is roughly 2 to 3 liters a day, more when side effects or heat take their toll. Why thirst gets quieter, and how to keep up anyway.
7 min read
What to eat on a GLP-1: foods that sit well and pull their weight
On a GLP-1, every small meal has a big job. The foods that digest comfortably with a slowed stomach, the ones that commonly backfire, and how to build a plate.
8 min read
GLP-1 nausea relief: what helps, what doesn't, and when to call
Nausea is the most common GLP-1 side effect, usually worst after dose changes and easing with time. Practical relief tactics and the red flags that need a clinician.
8 min read
Why GLP-1s can make you tired, and how to get your energy back
Tiredness on a GLP-1 is common and usually fixable: too few calories, too little protein, dehydration, or adjustment weeks. The checklist, in order.
7 min read
GLP-1 plateau: why the scale stalls and what actually helps
A GLP-1 plateau means 3 to 4 or more weeks without scale movement. Most are normal adaptation, not failure. What causes stalls, and the levers worth checking first.
8 min read
GLP-1 and muscle loss: how to keep what matters while the scale drops
In rapid weight loss a meaningful share can be lean mass. The two proven defenses are boring: a daily protein floor and progressive resistance training. The playbook.
8 min read
Food noise and GLP-1s: what the quiet actually feels like
Food noise is the constant background chatter about eating. GLP-1s are known for switching it off. What that quiet feels like, why it happens, and how to use it well.
7 min read
Weight regain after stopping a GLP-1: what the data says and what helps
Trials show most people regain a large share of lost weight within a year of stopping a GLP-1. Why it happens, who keeps it off, and what to build before stopping.
8 min read
Ozempic side effects: what to expect on the weekly semaglutide shot
A plain-language guide to Ozempic side effects — what's common, when each one shows up, how long it lasts, and the red flags that need a doctor the same day.
11 min read